CLINICAL TRIALS PROFILE FOR INDIUM IN-111 PENTETREOTIDE KIT

All Clinical Trials for indium in-111 pentetreotide kit

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001849 ↗	New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	1999-05-20	Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland. Between 10% and 20% of patients with hypercortisolism (Cushing Syndrome) have ectopic production of the hormone ACTH. Meaning, the hormone is not being released from the normal site, the pituitary gland. In many cases the ectopic ACTH is being produced by a tumor of the lung, thymus, or pancreas. However, in approximately 50% of these patients the source of the ACTH cannot be found even with the use of extensive imaging studies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and nuclear scans (111-indium pentetreotide). The ability of these tests to locate the source of the hormone production is dependent on the changes of anatomy and / or the dose and adequate uptake of the radioactive agent. The inability to detect the source of ectopic ACTH production often results in unnecessary pituitary surgery or irradiation. Unlike the previously described tests, positron emission tomography (PET scan) has the ability to detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This study will test whether fluorine-18-fluorodeoxyglucose (FDG), fluorine-18-dihydroxyphenylalanine (F-DOPA) or use of a higher dose of 111-indium pentetreotide can be used to successfully localize the source of ectopic ACTH production.
NCT00442533 ↗	Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors	Completed	CHI St. Luke's Health, Texas	Phase 2/Phase 3	2005-08-01	The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
NCT00442533 ↗	Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors	Completed	Excel Diagnostic Imaging Clinics	Phase 2/Phase 3	2005-08-01	The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
NCT00442533 ↗	Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors	Completed	RadioMedix	Phase 2/Phase 3	2005-08-01	The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.

Clinical Trial Conditions for indium in-111 pentetreotide kit

Condition Name

Condition Name for indium in-111 pentetreotide kit
Intervention	Trials
Neuroendocrine Tumors	2
Cushing Syndrome	2
Gastroenteropancreatic Neuroendocrine Tumors	1
Medulloblastoma	1

Condition MeSH

Condition MeSH for indium in-111 pentetreotide kit
Intervention	Trials
Carcinoid Tumor	3
Neuroendocrine Tumors	3
Syndrome	2
Cushing Syndrome	2

Clinical Trial Locations for indium in-111 pentetreotide kit

Trials by Country

Trials by Country for indium in-111 pentetreotide kit
Location	Trials
United States	4
Switzerland	1

Trials by US State

Trials by US State for indium in-111 pentetreotide kit
Location	Trials
Maryland	2
Iowa	1
Texas	1

Clinical Trial Progress for indium in-111 pentetreotide kit

Clinical Trial Phase

Clinical Trial Phase for indium in-111 pentetreotide kit
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 2	2
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for indium in-111 pentetreotide kit
Clinical Trial Phase	Trials
Completed	3
Terminated	1
Recruiting	1

Clinical Trial Sponsors for indium in-111 pentetreotide kit

Sponsor Name

Sponsor Name for indium in-111 pentetreotide kit
Sponsor	Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2
Radiomedix, Inc.	1
Radio Isotope Therapy of America	1

Sponsor Type

Sponsor Type for indium in-111 pentetreotide kit
Sponsor	Trials
Other	10
NIH	3
Industry	2

Indium in-111 pentetreotide kit Market Analysis and Financial Projection

Last updated: April 26, 2026

INDIUM IN-111 PENTETREOTIDE KIT: Clinical-Development Status, Market Snapshot, and Projection

What is the product and how is it positioned clinically?

Indium In-111 pentetotreotide (marketed as an imaging agent in a kit format) is used for somatostatin receptor imaging. The drug’s commercial identity is tied to nuclear medicine workflows, not chronic therapeutics. Its value proposition is procedure-level reimbursement and scan utilization, with demand linked to the incidence and diagnostic rates of somatostatin receptor–expressing tumors and downstream oncology treatment pathways.

Mechanism and use-case focus

• Target: somatostatin receptors (commonly SSTR2 in neuroendocrine tumor biology)
• Modality: diagnostic imaging using Indium In-111 labeled pentetotreotide
• Typical setting: staging, localization, and patient selection for therapies in neuroendocrine tumors and related indications (workflow driven by imaging protocols)

Regulatory label shape (commercially relevant)

• The marketed kit format implies a licensed preparation procedure under controlled labeling and handling instructions.
• Commercial adoption depends on institutional nuclear medicine adoption and payer acceptance of the imaging indication(s).

Where are the latest clinical trials likely to sit (and what does that imply for future pipeline risk)?

No current, public, regulator-trackable phase development “program” is apparent for this specific agent because its commercial life cycle is usually dominated by:

• Reformulations and packaging/kit updates
• Imaging protocol updates and new guideline incorporation
• Biospecimen/label refinement in labeling rather than new drug development

Given this lifecycle pattern for established radiopharmaceuticals, the market outlook is typically driven by:

• Patient volume and diagnostic intensity
• Imaging uptake under guidelines
• Competitive intensity from alternative imaging agents (other radiotracers) that shift practice patterns

Clinical risk profile

• Low “clinical de-risking risk” relative to novel small molecules/biologics because the agent is not in a classic late-stage growth pipeline.
• Risk concentrates on practice migration to newer receptor imaging options and competitive tracer adoption that reduce utilization of older Indium-based scans.

What is the competitive and market landscape for somatostatin-receptor imaging?

The key market dynamic in somatostatin receptor imaging is tracer substitution. Over the past decade, imaging has shifted toward alternatives that may offer better sensitivity or workflow advantages (including PET-based somatostatin receptor imaging). That shift compresses addressable utilization for older SPECT-based Indium In-111 imaging in some indications and geographies.

Competitive pressure channels

• Protocol migration: hospitals adopt PET-first imaging pathways where available and reimbursed
• Payer policy: reimbursement policies can favor newer imaging modalities or require additional justification for older scans
• Radiopharmacy capabilities: regional availability of alternative tracers changes utilization

Implications for Indium In-111 pentetotreotide

• Market growth is usually constrained and can trend with diagnostic practice intensity.
• The remaining demand base is where SPECT-based imaging remains standard, reimbursed, or operationally preferred.

What does the current market look like by demand drivers?

Indium In-111 pentetotreotide demand correlates with:

1. Neuroendocrine tumor (NET) diagnostic incidence and workup rates
2. Guideline adherence and imaging ordering behavior
3. Access to nuclear medicine facilities and tracer supply chain
4. Reimbursement coverage for SSTR imaging

In practice, the market behaves like a procedure market with a decaying or plateauing share versus PET-based alternatives, unless reimbursement and access conditions preserve SPECT utilization.

Market projection framework (procedure-driven, share-sensitive)

A usable projection model for this product has to separate:

• Total patient imaging addressable volume (rising with NET incidence and increased detection)
• Share of imaging modality (falling with PET adoption where it displaces SPECT)
• Geographic variability (PET availability and coverage differ)

Projection logic

• If NET incidence and detection increase faster than modality substitution, total demand can still grow modestly even with share loss.
• If modality substitution outpaces new case detection, the net market can decline.

Market analysis: scenario-based projection (directional, decision-grade)

Because the agent is an established radiopharmaceutical kit, the most investable question is not “will demand exist,” but “how much volume is retained after tracer substitution.”

Below is a directional scenario set you can apply to budgeting and capacity planning. Percentages represent relative market movement vs current base utilization (not absolute revenue).

Scenario set (3-year horizon)

Scenario	Modality substitution rate (vs base)	NET workup growth rate (vs base)	Expected Indium In-111 pentetotreotide market trend
Conservative	High	Low–moderate	Decline or flat-to-down
Base case	Moderate	Moderate	Flat to modest growth
Upside	Moderate	High (diagnostic expansion outweighs displacement)	Modest growth, risk-adjusted share retention

What determines which scenario dominates

• PET reimbursement expansion and national imaging pathway rules
• Radiotracer availability and supply chain stability
• Institutional adoption cycles and formulary dynamics

Is there any evidence of renewed clinical development that could expand use?

For a mature imaging kit, expansion typically comes from:

• Label updates tied to imaging guidance
• New clinical evidence that supports additional clinical decision points

Without a contemporaneous, publicly verifiable late-stage development signal for this specific product, the dominant commercial outcomes remain practice and reimbursement-driven, not new therapeutic efficacy demonstrations.

What are the key commercial metrics to track over the next 24 months?

To manage revenue stability and capacity strategy for Indium In-111 pentetotreotide, track:

• Imaging volume indicators: number of SSTR imaging scans reimbursed under relevant CPT/HCPCS pathways (where applicable)
• Site adoption: percent of major centers running SSTR imaging workflows with older SPECT scans vs PET-first protocols
• Formulary inclusion: hospital and imaging center coverage changes
• Regional tracer availability: supply continuity and ordering lead times for Indium-based kits
• Payer policy shifts: prior authorization changes that either restrict or continue coverage for SPECT imaging

What are patent and exclusivity considerations that matter commercially?

For established products like radiopharmaceutical imaging kits, competitive risk is usually driven by:

• Generic or equivalent radiolabeling kit availability
• Manufacturing capacity and regulatory approvals
• Exclusivity status and any data protection constraints

Commercial strategy depends on whether the product is protected primarily by composition-of-matter, formulation/process, or packaging/labeling protection, and whether equivalents erode share in specific geographies.

Actionable business takeaways

1. Treat Indium In-111 pentetotreotide as a procedure-share market where demand is tied to imaging utilization and reimbursement.
2. Model revenue with modality substitution as the primary downside driver and NET detection/workup expansion as the offset.
3. Use a scenario range (conservative decline to upside modest growth) for budgeting rather than assuming linear growth.
4. Invest operationally in supply reliability and site relationship management because institutional workflows decide ordering behavior.
5. Benchmark against PET-based SSTR imaging adoption in target geographies to estimate share retention.

---

Key Takeaways

• Indium In-111 pentetotreotide kit demand is driven by somatostatin receptor imaging utilization in neuroendocrine tumor workflows.
• Market direction is primarily determined by tracer substitution toward PET-based SSTR imaging, with NET detection growth as the main offset.
• Near-term outlook is best treated as flat-to-modest growth in base case, with meaningful downside risk in conservative substitution-heavy scenarios.
• Business planning should emphasize reimbursement monitoring, site adoption tracking, and supply chain continuity.

---

FAQs

1) What is the main market driver for Indium In-111 pentetotreotide?
SSTR imaging scan utilization tied to neuroendocrine tumor workup rates and payer coverage of SPECT-based imaging.

2) What is the biggest risk to future demand?
Practice migration toward PET-based somatostatin receptor imaging that displaces SPECT Indium-based scans.

3) Can demand still grow despite PET substitution?
Yes, if increases in NET detection and expanded diagnostic workup volume outweigh share loss to PET.

4) What metrics best indicate whether the market is expanding or contracting?
Reimbursed SSTR imaging scan volumes, hospital formulary inclusion, and changes in payer policy for SPECT-based SSTR imaging.

5) Is this a growth pipeline product or a mature product?
It behaves like a mature, workflow-driven radiopharmaceutical where commercial outcomes depend more on imaging practice and reimbursement than new clinical development phases.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (Database). https://clinicaltrials.gov/
[2] European Medicines Agency. Medicines (database). https://www.ema.europa.eu/en/medicines
[3] U.S. Food and Drug Administration. Drugs@FDA (database). https://www.accessdata.fda.gov/scripts/cder/daf/
[4] Radiopharmaceutical labeling and prescribing information sources (public regulatory databases and label repositories).